A must-read medication guide for patients with the targeted drug giritinib fumarate tablets for the treatment of leukemia

Treatment of leukemia is a complex and long process, and Gilitinib fumarate (Gilteritinib) tablets, as a targeted drug, play an important role in this process. The following is a must-read medication guide for giritinib fumarate:

1.Drug information: Giritinib fumarate is an oral targeted drug used to treat FLT3 mutation-positive acute myeloid leukemia (AML). It blocks the proliferation and survival of leukemia cells by inhibiting the abnormally active FLT3 receptor kinase.

2.Dose: The dosage is usually determined by the doctor based on the patient's specific condition and severity of the condition. Patients must use the medication accurately and strictly in accordance with the doctor's instructions, and are not allowed to adjust the dosage without authorization.

3.Dosing time: Giritinib fumarate is usually taken orally every day. It should be taken at the same time every day as much as possible, and it should be used continuously according to the doctor's instructions.

4.Diet and administration: Giritinib fumarate can be taken with food or on an empty stomach. Patients should avoid drinking alcohol while taking the drug because alcohol may increase the toxicity of the drug.

5.Drug interactions: Patients should avoid concurrent use of other drugs while taking giritinib fumarate, especially drugs that may affect cardiac function or are related to drug metabolism. You should talk to your doctor before starting a new medicine.

6.Pregnancy and lactation: Giritinib fumarate may cause harm to the fetus, so pregnant women should avoid using this drug. At the same time, women who are breastfeeding should also stop breastfeeding to prevent the drug from being passed to the baby through breast milk.

7.Adverse reactions:Giritinib fumarate may cause some adverse reactions, including but not limited to nausea, vomiting, diarrhea, fatigue, headache, rash, etc. Patients should report any discomfort or adverse reactions to their doctor.

8.Treatment effect and monitoring: Patients should undergo regular blood tests and other clinical evaluations while using giritinib fumarate to evaluate the effectiveness and safety of the treatment, and adjust the treatment plan in a timely manner.

9.Relapse and drug resistance: Although giritinib fumarate can effectively control the condition of leukemia, there is still a risk of relapse and drug resistance. Patients should pay close attention to changes in their condition and conduct regular follow-up and monitoring.

10.Doctor's guidance: During the use of gilitinib fumarate, patients should always follow the doctor's instructions and recommendations, conduct regular follow-up visits, and maintain close contact with the doctor during the treatment process.

In general, patients should strictly follow the doctor's instructions and prescriptions while using giritinib fumarate, promptly report any adverse reactions, and conduct regular monitoring and follow-up to ensure the effectiveness and safety of the treatment. At the same time, patients should also understand drug-related information, including dosage, medication time, adverse reactions, precautions, etc., in order to better manage the disease and improve treatment effects.